



RECEIVED
AUG 14 2001 #11

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: RAMNARAYAN et al.


Serial No.: 09/709,905

Filed: November 10, 2000

For: **USE OF COMPUTATIONALLY DERIVED
PROTEIN STRUCTURES OF GENETIC
POLYMORPHISMS IN
PHARMACOGENOMICS FOR DRUG
DESIGN AND CLINICAL APPLICATIONS**

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents,
Washington, D.C. 20231, on this date.

07/30/2001
Date


Robert Wickman

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
Washington, D.C. 20231


Sir:

Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

Under **CONTINUING DATA AS CLAIMED BY APPLICANT**, please insert the following Priority Information:

THIS APPLN IS A CIP OF 09/438,566 11/10/1999
AND 09/704,362 11/01/2000.

Applicants respectfully request that this error be corrected and Applicants be provided a new Official Filing Receipt.



U.S.S.N. 09/709,905
RAMNARAYAN et al.
REQUEST FOR CORRECTED FILING RECEIPT

RECEIVED

AUG 14 2001

TECH CENTER 1600/2900




The Commissioner is hereby authorized to charge any fee, including that submitted herewith if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE LLP.

By:


Stephanie Seidman
Registration No. 33,779

SLS/rmw
Attorney Docket 24737-1906C
Address all correspondence to:
HELLER EHRMAN WHITE & McAULIFFE LLP.
4350 La Jolla Village Drive, 6th Floor
San Diego, California 92122-1246
Telephone: (858) 450-8400
E-mail: dhall@HEWM.com




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/709,905	11/10/2000	1631	2744	24737-1906C	46	67	9

CONFIRMATION NO. 3606

FILING RECEIPT



OC000000006275716

STEPHANIE L. SEIDMAN, ESQ.
HELLER EHRMAN WHITE & MCAULIFFE LLP
6TH FLOOR
4350 LA JOLLA VILLAGE DRIVE
SAN DIEGO, CA 92122-1246

Date Mailed: 07/10/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)


Kalyanaraman Ramnarayan, San Diego, CA;
Edward T. Maggio, San Diego, CA;
P. Patrick Hess, San Clemente, CA;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CIP OF 09/438,566 11/10/1999 ABN

Foreign Applications

AND 09/704,362 11/01/2000



If Required, Foreign Filing License Granted 07/09/2001

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

Title

Use of computationally derived protein structures of genetic polymorphisms in pharmacogenomics for drug design and clinical applications



Preliminary Class
702

RECEIVED

Page 2 of 3
AUG 14 2001

TECH CENTER 1600/2900

Data entry by : NGUYEN, NGAN

Team : OIPE

Date: 07/10/2001





**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

RECEIVED
Page 3 of 3
AUG 14 2001
TECH CENTER 1600/2900

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231